Pe­ter Dia­man­dis' right hand man Sergey Young wants to re­verse ag­ing via his $100M Longevi­ty Vi­sion Fund

In­spired by British bil­lion­aire Jim Mel­lon, chair­man of an­ti-ag­ing up­start biotech ven­ture Ju­ve­nes­cence, Sergey Young un­veiled a $100 mil­lion fund on Mon­day to cat­alyze the de­vel­op­ment of a com­pre­hen­sive so­lu­tion to coun­ter­act the dam­ag­ing con­se­quences of ag­ing.

“I’ve nev­er looked like my age…and with my name, I think it was pre­de­ter­mined that I was go­ing to work in the space (of ag­ing),” Young told End­points News. The 47-year-old con­sid­ers him­self a prod­uct of Pe­ter Dia­man­dis — the man be­hind the non-prof­it XPRIZE and ven­ture cap­i­tal fund BOLD Cap­i­tal Part­ners — and is in charge of all things longevi­ty at both or­ga­ni­za­tions.

Jim Mel­lon

Like Mel­lon, who penned Ju­ve­nes­cence: In­vest­ing in the Age of Longevi­ty pri­or to the launch of the com­pa­ny Ju­ve­nes­cence, Young is in the em­bry­on­ic stage of writ­ing his own book de­signed to de­code the sci­ence of ag­ing for the mass­es. Mean­while, his $100 mil­lion Longevi­ty Vi­sion Fund will back or­ga­ni­za­tions who are work­ing on tech­nol­o­gy to re­verse the ag­ing process and pro­long healthy hu­man life.

“Adding 20 to 30 healthy years on a per­son’s life is like­ly to be the largest mar­ket op­por­tu­ni­ty on earth. The con­ver­gence of Genome Se­quenc­ing, AI & Cel­lu­lar Med­i­cine will en­able break­throughs that will make 100 years old the new 60. I’m proud through our BOLD Cap­i­tal part­ner­ship to sup­port Sergey Young and the Longevi­ty Vi­sion Fund,” Pe­ter Dia­man­dis said in a state­ment.

Young did not dis­close the deals his fund is cur­rent­ly ex­plor­ing but laid out the ar­eas he is in­ter­est­ed in pur­su­ing.

Pe­ter Dia­man­dis

“We are cur­rent­ly work­ing on 6 deals…and are look­ing at all the usu­al sus­pects in terms of themes” he said. These ar­eas in­clude ear­ly de­tec­tion of se­ri­ous dis­eases us­ing ul­tra­sound tech­nol­o­gy; ear­ly di­ag­nos­tics for heart, can­cer and neu­rode­gen­er­a­tive dis­eases; stem-cell and mi­cro­bio­me-based ther­a­peu­tics; and big da­ta as well as AI-based ap­pli­ca­tions.

Un­sur­pris­ing­ly, Young is in di­a­logue with Alex Zha­voronkov’s AI shop at In­sil­i­co Med­i­cine. Zha­voronkov has deep con­nec­tions in the R&D space — last year he raised funds at the be­hest of Shang­hai high-fly­er WuXi AppTec, Sin­ga­pore’s Temasek, Pe­ter Dia­man­dis and Ju­ve­nes­cence.

“We do plan to par­tic­i­pate in the next round of fund­ing to be­come a share­hold­er of In­sil­i­co,” Young said. It is a mu­tu­al ap­pre­ci­a­tion so­ci­ety here at the Longevi­ty Lead­ers Con­gress in Lon­don, where Zha­voronkov is heard in­tro­duc­ing Young as a vi­sion­ary fund man­ag­er to a con­fer­ence at­tendee. Young, Zha­voronkov, Mel­lon and a host of oth­ers high-pro­file C-suite reg­u­lars in­volved in ag­ing R&D have flocked to a ho­tel near the renowned St Paul’s Cathe­dral to dis­cuss re­cent de­vel­op­ments in an­ti-ag­ing. In the first keynote pan­el of the day, vice pres­i­dent of Ju­ve­nes­cence-backed AgeX Aubrey de Grey am­bi­tious­ly claims that that longevi­ty space will even­tu­al­ly “dwarf the dot­com boom.”

Alex Zha­voronkov

But more fund­ing is nec­es­sary, Zha­voronkov told End­points News at the con­fer­ence. Oth­er than Google’s an­ti-ag­ing biotech Cal­i­co that has seen a large in­flux of funds, the field of an­ti-ag­ing is ripe for in­vest­ment, he said.

For long-time in­vestor and ven­ture cap­i­tal­ist Young, who has in­sight in­to the ag­ing R&D ef­fort with­in the US and to a less­er ex­tent in the UK, Chi­na and In­dia’s siz­able pop­u­la­tions pose com­pelling prospects for deals for his fund.

“In the next decade, ad­vance­ments will al­low us to be a lot more pre­dic­tive and pre­ven­ta­tive in the most dam­ag­ing dis­eases,” he said. “I’m think­ing AI-en­abled med­i­cine will em­pow­er doc­tors…tech­no­log­i­cal ad­vances to im­prove sleep­ing and med­i­ta­tion will emerge — and these are an es­sen­tial part of a healthy, long life, along with a plant-based di­et.”


Im­age: Sergey Young. LONGEVI­TY VI­SION FUND

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

Alaa Halawaa, executive director at Mubadala’s US venture group

The ven­ture crew at Mubadala are up­ping their biotech cre­ation game, tak­ing care­ful aim at a new fron­tier in drug de­vel­op­ment

It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business.

Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development.

“Jim and I have known each other for the past 15 years through Genentech collaborations. We met over coffee, and he was telling me about this concept of the company that he was thinking of,” says Hannoush. “And I got immediately intrigued by it because I knew that this could open up a big space in terms of adding a new modality in drug discovery that is desperately needed in pharma.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Flare Therapeutics biochemists Yong Li (L) and Valerie Vivat

A $123M Flare will get Third Rock on­col­o­gy biotech in­to the clin­ic this year

Flare Therapeutics will start its first human trial this year with an investigational urothelial cancer drug after pulling together a $123 million Series B from Big Pharmas, VCs and its incubator, Third Rock Ventures.

Launched in 2021 on the idea that a biotech could finally succeed at drugging the much-sought-after but stubborn transcription factor, Flare Therapeutics said Wednesday it is now primed for the clinic after closing its large financing haul earlier this year. The raise is a relatively stark figure in a tough startup financing environment but further buoys the upbeat signals coming out of other Third Rock biotechs in recent weeks, including the $200 million CARGO Therapeutics and $100 million Rapport Therapeutics rounds.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

Francesco Marincola, newly-appointed Sonata Therapeutics CSO

Kite's head of re­search leaves for Flag­ship start­up Sonata

Another leader is departing Kite Pharma, and will to spend the “last part” of his career exploring how cancer evades the immune system.

Kite’s senior VP and global head of cell therapy research Francesco Marincola left the Gilead CAR-T unit last week for Sonata Therapeutics. Flagship last May unveiled the startup, which was pieced together from two fledgling biotechs Inzen and Cygnal Therapeutics. As CSO, Marincola will lead Sonata’s push to reprogram cancer cells to make them more immunogenic.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

Rohan Palekar, 89bio CEO

89bio’s PhII da­ta add to quick suc­ces­sion of NASH read­outs as field seeks turn­around

89bio said its drug was better than placebo at lessening fibrosis without worsening nonalcoholic steatohepatitis, or NASH, in two of three dose groups.

The San Francisco biotech said it thinks the Phase IIb data pave the way for a potential Phase III, following in the footsteps of another biotech in its drug class, Akero Therapeutics. To fund a late-stage study, CEO Rohan Palekar told Endpoints News 89bio “would need to raise additional capital,” with the company having about $188 million at the end of last year.

FDA in­di­cates will­ing­ness to ap­prove Bio­gen ALS drug de­spite failed PhI­II study

Ahead of Wednesday’s advisory committee hearing to discuss Biogen’s ALS drug tofersen, the FDA appeared open to approving the drug, newly released briefing documents show.

Citing the need for flexibility in a devastating disease like ALS, regulators signaled a willingness to consider greenlighting tofersen based on its effect on a certain protein associated with ALS despite a failed pivotal trial. The documents come after regulatory flexibility was part of the same rationale the agency expressed when approving an ALS drug last September from Amylyx Pharmaceuticals, indicating the FDA’s openness to approving new treatments for the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

Who are the women break­ing bar­ri­ers in drug de­vel­op­ment? Nom­i­nate them for End­points' an­nu­al re­port

Today, we’re opening nominations for our fifth annual Women in Biopharma R&D special report.

Over the last four years, we’ve honored 80 women whose extraordinary accomplishments have changed the game in biopharma R&D. We’re looking for big thinkers, scientists, executives and other enterprising women who are breaking barriers in drug development and inspiring the next generation of leaders.

Roche and Lil­ly team up to de­vel­op blood test to de­tect ear­ly signs of Alzheimer's

Eli Lilly is teaming up with Roche to help develop a blood test to detect early signs of Alzheimer’s disease and determine whether a patient should go for further confirmatory testing.

Roche’s Elecsys Amyloid Plasma Panel (EAPP) measures pTau 181 protein assay and APOE E4 assay in human blood plasma – elevations in pTau 181 are present in the early stages of Alzheimer’s, while the presence of APO E4 is the most common genetic risk factor for the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.

Josep Bassaganya-Riera, NImmune Biopharma

Ex­clu­sive: Af­ter get­ting his drug back, Lan­dos founder as­sem­bles new start­up for the big PhI­II test

By the time Josep Bassaganya-Riera stepped down as founding CEO of Landos Biopharma in 2021, the company had racked up Phase II data for its top autoimmune program, completed what he called a positive end-of-Phase-II meeting with the FDA and plans to launch pivotal Phase III trials.

Since then, though, the new leaders at Landos have reshuffled their plans for the drug, omilancor, first announcing they will run a Phase IIb ahead of a Phase III and eventually shelving it altogether.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.